Grant of Options

RNS Number : 1162B

Destiny Pharma PLC

04 June 2019

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Grant of Options

Brighton, United Kingdom - 4 June 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that it has granted options ("Options") over 335,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") (representing 0.76 per cent. of the Company's issued share capital) to certain employees of the Company, including the below Director and PDMR.

Name	Position	Options Issued	Total Options Held Post Issue
Neil Clark	Chief Executive Officer	200,000	544,305
Jesus Gonzales	PDMR	75,000	75,000

The Options represent awards under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on 25 January 2018 for EMI and non-tax advantage options. The Options have been granted at a price of £0.01 per Ordinary Share, which will vest on the third anniversary of the date of grant and are exercisable for ten years thereafter.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[e-mail]

[phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

[e-mail]

[phone]

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Neil Clark
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options over ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST      GB00BDHSP575
b)	Nature of the transaction	Grant of Options
c)	Price(s) and volume(s)	1 pence per Ordinary Share 200,000 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	4 June 2019
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jesus Gonzales
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options over ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST      GB00BDHSP575
b)	Nature of the transaction	Grant of Options
c)	Price(s) and volume(s)	1 pence per Ordinary Share 75,000 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	4 June 2019
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

DSHBXGDLLXGBGCS